PDL-1 expression of tumor was significantly associated with a shorter PFS [92], and for the researches of its receptor, namely PD-1, showed that cumulative response rates to anti-PD-1 antibody were 18% among NSCLC patients according to a clinical trial in America (14 of 76 patients), which provided a kind of new method to NSCLC treatment [93]. Here, CD274 is linked to non-small cell lung carcinoma.